DexCom, Inc. (DXCM) Coverage Initiated by Analysts at Barclays PLC

Stock analysts at Barclays PLC initiated coverage on shares of DexCom, Inc. (NASDAQ:DXCM) in a report issued on Friday. The firm set an “equal weight” rating on the medical device company’s stock.

A number of other analysts have also recently commented on DXCM. BMO Capital Markets reaffirmed an “outperform” rating and set a $90.00 target price (down from $105.00) on shares of DexCom in a report on Wednesday, August 2nd. BidaskClub raised shares of DexCom from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 9th. Piper Jaffray Companies reissued an “overweight” rating and issued a $78.00 price objective (down from $87.00) on shares of DexCom in a research note on Wednesday, August 16th. Robert W. Baird reissued a “hold” rating and issued a $79.00 price objective on shares of DexCom in a research note on Sunday, September 10th. Finally, ValuEngine raised shares of DexCom from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $87.64.

DexCom (NASDAQ:DXCM) opened at 72.35 on Friday. The company has a 50-day moving average of $72.36 and a 200-day moving average of $74.17. The stock’s market capitalization is $6.26 billion. DexCom has a 1-year low of $57.68 and a 1-year high of $94.79.

DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. During the same period in the prior year, the company earned ($0.24) earnings per share. The firm’s revenue was up 24.3% on a year-over-year basis. Analysts anticipate that DexCom will post ($0.77) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (DXCM) Coverage Initiated by Analysts at Barclays PLC” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/09/15/dexcom-inc-dxcm-coverage-initiated-by-analysts-at-barclays-plc.html.

In other news, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $69.77, for a total value of $418,620.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $78.19, for a total transaction of $113,375.50. The disclosure for this sale can be found here. Insiders have sold 26,223 shares of company stock valued at $1,881,249 in the last quarter. 1.70% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in DXCM. Janus Henderson Group PLC lifted its holdings in shares of DexCom by 101,699.8% in the 2nd quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock worth $499,522,000 after acquiring an additional 6,822,023 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of DexCom by 5,000.4% in the 1st quarter. BlackRock Inc. now owns 4,160,862 shares of the medical device company’s stock worth $352,550,000 after acquiring an additional 4,079,283 shares during the last quarter. Winslow Capital Management LLC bought a new stake in shares of DexCom in the 2nd quarter worth about $117,451,000. FMR LLC lifted its holdings in shares of DexCom by 9.9% in the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after acquiring an additional 978,898 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of DexCom by 27.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,242,928 shares of the medical device company’s stock worth $237,221,000 after acquiring an additional 696,199 shares during the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply